Abstract: The invention is in the field of molecular diagnosis of medical diseases and their treatment. More in particular, it provides methods and means for detecting hypertension, more in particular essential primary hypertension, even more in particular NOX5-dependent hypertension. The invention also provides methods for the treatment of hypertension, in particular essential primary hypertension, more in particular NOX5-dependent hypertension. The invention also provides theragnostics, wherein therapy is combined with diagnosis, more in particular wherein the level of NOX5 is determined in a sample from a subject and wherein the subject is treated with NOX5 inhibitors or compounds that decrease the levels of NOX5 if the NOX5 levels are above a certain threshold value.

Abstract: The present invention relates to a medicament for treating addiction craving which is characterized in that the medicament consists of a combination of two administration forms, one of the administration forms continuously releasing at least one modulator of nicotinic receptors and the other administration form enabling a rapid entry of galanthamine into the central nervous system, as well as a two-stage method for the therapy of substance craving through modulation of neuronal nicotinic receptors, wherein a permanent treatment with a pharmaceutical administration form which continuously delivers a modulator of nicotinic receptors is supplemented upon the appearance of a strong craving for a substance by administering galanthamine or a pharmacologically acceptable salt thereof by means of an administration form which enables rapid entry of this modulator into the central nervous system.

Abstract: Use of deoxypeganine, as a free base or as acid addition salt, for the production of drugs intended for the therapy of clinical depression, especially of depression connected with dementia or abuse of alcohol and/or nicotine.

Abstract: The present invention relates to an active ingredient combination composed of at least one modulator of the cholinergic system with at least one substance having antiexcitatory activity for pharmacological addictive substance or intoxicant therapy, in particular of alcoholism.

Abstract: The present invention relates to an active ingredient combination composed of at least one modulator of the cholinergic system with at least one substance blocking central opioid receptors for the pharmacological treatment of nicotine dependence.